代谢型谷氨酸受体5与应激障碍:受体影像研究的启示
本文综述了正电子发射断层扫描(PET)研究关于代谢型谷氨酸受体5(mGluR5)在应激相关精神障碍中的发现,重点讨论重性抑郁障碍(MDD)。PET研究显示MDD中mGluR5无差异或降低,可能反映MDD异质性;mGluR5特异性调节尚未在MDD和双相障碍中显示抗抑郁疗效。创伤后应激障碍和强迫症中mGluR5可能上调,但研究较少。
要点
- PET研究显示MDD中mGluR5无差异或降低,可能反映疾病异质性。
- mGluR5特异性调节尚未在MDD和双相障碍中显示抗抑郁疗效。
- PTSD和强迫症中mGluR5可能上调,但拮抗可能减少恐惧消退,需进一步研究。
核心结论
- mGluR5是应激相关精神障碍的潜在治疗靶点,但所需调节水平和类型尚不明确。
- mGluR5特异性调节尚未在MDD和双相障碍中显示抗抑郁疗效。
研究设计与样本
- 综述聚焦PET研究关于mGluR5在应激障碍中的发现,重点为MDD。
主要发现
- PET研究报道MDD中mGluR5无差异或降低,可能反映MDD异质性。
- mGluR5特异性调节尚未在MDD和双相障碍中显示抗抑郁疗效。
- 氯胺酮可能部分通过显著调节mGluR5起作用,但mGluR5下调在氯胺酮抗抑郁反应中的具体作用尚不清楚。
- 双相障碍中mGluR5研究较少,初步研究提示mGluR5特异性治疗可能对抑郁和躁狂状态均有帮助,但所需调节方向可能依赖状态。
- PTSD和强迫症研究较少,但有证据表明mGluR5上调;mGluR5拮抗可能减少恐惧条件化,但也可能减少恐惧消退。
临床怎么用
- mGluR5调节用于应激障碍治疗尚处研究阶段,临床需谨慎。
- 需进一步研究确定mGluR5调节的水平与类型(正/负变构调节或完全拮抗)以转化为改进疗法。
局限性
- mGluR5调节可能诱导显著副作用。
- PTSD和强迫症研究较少,mGluR5调节在这些疾病治疗中的作用需研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The metabotropic glutamatergic receptor subtype 5 (mGluR5) may represent a promising therapeutic target for stress-related psychiatric disorders. Here, we describe mGluR5 findings in stress disorders, particularly major depressive disorder (MDD), highlighting insights from positron emission tomography studies. Positron emission tomography studies report either no differences or lower mGluR5 in MDD, potentially reflecting MDD heterogeneity. Unlike the rapidly acting glutamatergic agent ketamine, mGluR5-specific modulation has not yet shown antidepressant efficacy in MDD and bipolar disorder. Although we recently showed that ketamine may work, in part, through significant mGluR5 modulation, the specific role of mGluR5 downregulation in ketamine's antidepressant response is unclear. In contrast to MDD, there has been much less investigation of mGluR5 in bipolar disorder, yet initial studies indicate that mGluR5-specific treatments may aid in both depressed and manic mood states. The direction of modulation needed may be state dependent, however, limiting clinical feasibility. There has been relatively little study of posttraumatic stress disorder or obsessive-compulsive disorder to date, although there is evidence for the upregulation of mGluR5 in these disorders. However, while antagonism of mGluR5 may reduce fear conditioning, it may also reduce fear extinction. Therefore, studies are needed to determine the role mGluR5 modulation might play in the treatment of these conditions. Further challenges in modulating this prevalent neurotransmitter system include potential induction of significant side effects. As such, more research is needed to identify level and type (positive/negative allosteric modulation or full antagonism) of mGluR5 modulation required to translate existing knowledge into improved therapies.
引用
- Esterlis I, Holmes SE, Sharma P, et al. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies. Biol Psychiatry. 2017. PMID: 29100629. doi:10.1016/j.biopsych.2017.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。